Cargando…
Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report
RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which ra...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310527/ https://www.ncbi.nlm.nih.gov/pubmed/30544475 http://dx.doi.org/10.1097/MD.0000000000013563 |
_version_ | 1783383453138419712 |
---|---|
author | Karino, Kohei Fujieda, Yuichiro Kawamura, Takuya Abe, Nobuya Shimoyama, Shuhei Kono, Michihito Kato, Masaru Yasuda, Shinsuke Atsumi, Tatsuya |
author_facet | Karino, Kohei Fujieda, Yuichiro Kawamura, Takuya Abe, Nobuya Shimoyama, Shuhei Kono, Michihito Kato, Masaru Yasuda, Shinsuke Atsumi, Tatsuya |
author_sort | Karino, Kohei |
collection | PubMed |
description | RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which radiographically mimicked benign tumor. PATIENT CONCERNS: A 72-year-old man presented typical characteristic cutaneous manifestations and proximal muscle weakness with elevated levels of myogenic enzymes. An anterior mediastinal tumor was detected by computed tomography (CT) scan and radiographically assessed to be benign with distinct borders and little enhancement. DIAGNOSES: DM with anti-TIF1γ antibody and thymic carcinoma. INTERVENTIONS: Thymic carcinoma was completely resected by surgery. DM was induced into remission with glucocorticoid treatment. OUTCOMES: The serum level of myogenic enzyme remained within normal range under low-dose glucocorticoid maintenance. No evidence of carcinoma recurrence with CT scan was observed at 1-year follow up. LESSONS: The present case indicated that anti-TIF1γ antibody would play a role as the “autoimmune tumor marker” in patients with inflammatory myopathy. |
format | Online Article Text |
id | pubmed-6310527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63105272019-01-14 Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report Karino, Kohei Fujieda, Yuichiro Kawamura, Takuya Abe, Nobuya Shimoyama, Shuhei Kono, Michihito Kato, Masaru Yasuda, Shinsuke Atsumi, Tatsuya Medicine (Baltimore) Research Article RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which radiographically mimicked benign tumor. PATIENT CONCERNS: A 72-year-old man presented typical characteristic cutaneous manifestations and proximal muscle weakness with elevated levels of myogenic enzymes. An anterior mediastinal tumor was detected by computed tomography (CT) scan and radiographically assessed to be benign with distinct borders and little enhancement. DIAGNOSES: DM with anti-TIF1γ antibody and thymic carcinoma. INTERVENTIONS: Thymic carcinoma was completely resected by surgery. DM was induced into remission with glucocorticoid treatment. OUTCOMES: The serum level of myogenic enzyme remained within normal range under low-dose glucocorticoid maintenance. No evidence of carcinoma recurrence with CT scan was observed at 1-year follow up. LESSONS: The present case indicated that anti-TIF1γ antibody would play a role as the “autoimmune tumor marker” in patients with inflammatory myopathy. Wolters Kluwer Health 2018-12-10 /pmc/articles/PMC6310527/ /pubmed/30544475 http://dx.doi.org/10.1097/MD.0000000000013563 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Karino, Kohei Fujieda, Yuichiro Kawamura, Takuya Abe, Nobuya Shimoyama, Shuhei Kono, Michihito Kato, Masaru Yasuda, Shinsuke Atsumi, Tatsuya Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report |
title | Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report |
title_full | Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report |
title_fullStr | Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report |
title_full_unstemmed | Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report |
title_short | Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: A case report |
title_sort | anti-tif1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an “autoimmune tumor marker”: a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310527/ https://www.ncbi.nlm.nih.gov/pubmed/30544475 http://dx.doi.org/10.1097/MD.0000000000013563 |
work_keys_str_mv | AT karinokohei antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT fujiedayuichiro antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT kawamuratakuya antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT abenobuya antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT shimoyamashuhei antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT konomichihito antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT katomasaru antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT yasudashinsuke antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport AT atsumitatsuya antitif1gantibodypredictedmalignancyofthymictumorwithdermatomyositisasanautoimmunetumormarkeracasereport |